Institute for Cancer Research


Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded.

The Institute has internationally strong research groups within biochemistry, cell and tumor biology, genetics, radiation biology, immunology and cancer prevention. For more than 30 years there has been a close interaction between researchers at the Institute and cancer surgeons, oncologists and pathologists. This emphasis on translational science has resulted in numerous clinical protocols based on in-house research, and the Institute is a key partner in the Comprehensive Cancer Center, organizationally under the Division of Surgery and Cancer Treatment at Oslo University Hospital.

Gunnar Sæter<br>Scientific director
Gunnar Sæter
Scientific director

Scientific production - Institute for Cancer Research

  Publications Doctoral theses
 2016  so far  
2015 220 21
2014 176 25
2013 197 27
2012 175 18
2011 201 22

Annual report 2015 (pdf format)


Latest news

Human lung macrophages are self-maintained for several years

First author Ibon Eguiluz-Gracia (left) and senior author Espen Bækkevold
First author Ibon Eguiluz-Gracia (left) and senior author Espen Bækkevold

The classical view of tissue macrophages is that they are continuously replaced by blood monocytes, but a paper first-authored by Ibon Eguiluz-Gracia (photo) from Frode Jahnsen's group at the Department of Pathology at OUH and the Centre for Immune Regulation at UiO, recently published in Thorax (journal impact factor 8.3), show that human alveolar macrophages are self-maintained within the lungs for many years. This may be important for development of chronic graft rejection, which is a common complication after lung transplantation and remains the major obstacle to better long-term outcomes.
Furthermore, as pointed out in the accompanying Editorial in Thorax, this study has potential implications for treatment of patients with alveolar proteinosis and COPD. 


Gathering Friday October 28th 10-12 at UiO:

Announcement of research funding from the Norwegian Cancer Society


The board of the Norwegian Cancer Society will October 24th decide which research projects that will be funded. All applications have been peer reviewed internationally. Those receiving funding will be contacted prior to the event.
The announcement event take place on Friday October 28th at 10-10 AM in the "Professorboligen" at the University of Oslo. There will be talks held by a scientist, a fund-raiser, and a personal story will be told. There will also be an artistic peformance, and refreshments will be served.

Final date for registration: October 25th


Making therapeutic antibodies from scratch

Mouldy Sioud<br>Senior author
Mouldy Sioud
Senior author

Mouldy Sioud (photo) from the Department of Immunology at the Instiute for Cancer Research is senior author on an article recently published in Oncotarget (journal impact factor 6.36), entitled "Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth".


Lina Prasmickaite's work presented in popularised form

Lina Prasmickaite
Lina Prasmickaite

Lina Prasmickaite from the Department of Tumor Biology at the Institute for Cancer Research has spent several years studying why certain cancer cells become immune against treatment. Her research on this subject is presented in a popular science article (in Norwegian) recently published by the Norwegian Cancer Society.


Oslo University Hospital research seminar Monday October 10th

Medical imaging in cardiac research


Welcome to the next Oslo University Hospital (OUH) research seminar entitled "Medical imaging in cardiac research".

Time: Monday, October 10th, 2016, at 14:30 – 16:00.
Place: Green Auditorium, Rikshospitalet, Sognsvannsveien 20, Oslo.

Speakers: Ivar Sjaastad, Emil Espe, Einar Hopp, Thor Edvardsen and Espen Remme.


Focus on personalized medicine and the MetAction study

Gunhild Mælandsmo (left) and Kjersti Flatmark
Gunhild Mælandsmo (left) and Kjersti Flatmark

The Norwegian Cancer Society have recently published a popular science article (in Norwegian) presenting the work of Gunhild Mælandsmo and Kjersti Flatmark, both from the Department of Tumor Biology at the Institute for Cancer Research. The scientists explains how their research on colorectal cancer may improve the methods of personalized medicine, and how the MetAction study, which is supported by the Norwegian Cancer Society, may contribute to the development of more precise cancer treatments in the future.